Personalis to Post Q2 2020 Earnings of ($0.32) Per Share, Oppenheimer Forecasts (NASDAQ:PSNL)

Personalis (NASDAQ:PSNL) – Analysts at Oppenheimer lifted their Q2 2020 earnings per share estimates for shares of Personalis in a research note issued to investors on Wednesday, June 24th. Oppenheimer analyst K. Degeeter now anticipates that the company will earn ($0.32) per share for the quarter, up from their prior estimate of ($0.34). Oppenheimer currently has a “Buy” rating and a $24.00 target price on the stock. Oppenheimer also issued estimates for Personalis’ FY2020 earnings at ($1.30) EPS.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.03). Personalis had a negative net margin of 40.60% and a negative return on equity of 26.28%. The business had revenue of $19.16 million during the quarter, compared to the consensus estimate of $16.80 million.

A number of other brokerages have also commented on PSNL. Zacks Investment Research lowered Personalis from a “hold” rating to a “sell” rating in a report on Friday, June 26th. ValuEngine raised Personalis from a “hold” rating to a “buy” rating in a report on Friday, March 13th. Morgan Stanley upped their price objective on Personalis from $13.00 to $14.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, BidaskClub lowered Personalis from a “strong-buy” rating to a “buy” rating in a report on Friday, May 29th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $20.20.

Shares of NASDAQ PSNL opened at $12.97 on Monday. The stock’s fifty day moving average price is $12.37 and its two-hundred day moving average price is $10.17. Personalis has a one year low of $4.27 and a one year high of $27.59. The firm has a market cap of $403.99 million and a price-to-earnings ratio of -8.06.

Several hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its position in shares of Personalis by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 109,737 shares of the company’s stock worth $1,196,000 after buying an additional 1,062 shares during the last quarter. Victory Capital Management Inc. raised its position in Personalis by 110.9% in the fourth quarter. Victory Capital Management Inc. now owns 3,043 shares of the company’s stock valued at $33,000 after purchasing an additional 1,600 shares during the last quarter. Deutsche Bank AG raised its position in Personalis by 95.5% in the first quarter. Deutsche Bank AG now owns 6,081 shares of the company’s stock valued at $49,000 after purchasing an additional 2,971 shares during the last quarter. UBS Group AG raised its position in Personalis by 37.2% in the first quarter. UBS Group AG now owns 14,907 shares of the company’s stock valued at $120,000 after purchasing an additional 4,042 shares during the last quarter. Finally, BNP Paribas Arbitrage SA raised its position in Personalis by 432.5% in the first quarter. BNP Paribas Arbitrage SA now owns 5,511 shares of the company’s stock valued at $44,000 after purchasing an additional 4,476 shares during the last quarter. Institutional investors and hedge funds own 60.92% of the company’s stock.

In related news, major shareholder Lightspeed Venture Partners Se bought 77,797 shares of Personalis stock in a transaction dated Monday, June 1st. The shares were bought at an average cost of $12.98 per share, with a total value of $1,009,805.06. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 8.20% of the company’s stock.

Personalis Company Profile

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT platform, a clinical-grade, next generation sequencing and analysis platform that enables the development of ImmunoID NeXT tumor biopsy and liquid biopsy, as well as provides analysis of tumor and immune microenvironment from a single limited tissue sample, tumor molecular profiling for cancer patients, and anticipates future cancer biomarkers.

See Also: Book Value Of Equity Per Share – BVPS Explained

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.